Annual Report 2011/12 published
People at the PEI, research and the regulation of medicinal products: These are the key themes of the Annual Report 2011/12 of the Paul-Ehrlich-Institut. Renowned experts and a highly dedicated staff are the most important asset of a federal institute that operates at both a national and an international level – the report introduces some of these people.
Submission via CESP - Common European Submission Platform
Since October 2012 it is possible to submit applications for marketing authorisations, authorisation of tissue preparations and deviations and others in the national, MRP or DCP procedures through the improved Common European Submission Platform (CESP). When submitting through the CESP, a parallel sending of CDs or DVDs to the Paul-Ehrlich-Institut (PEI) is not necessary. The PEI advises all companies / applicants to start using CESP.
Oncolytic viruses for targeted attack on cancer stem cells generated
Scientists at the Paul-Ehrlich-Institut (PEI) have successfully created oncolytic viruses which effectively target CD133-positive cancer stem cells to infect and kill them. In animal experiments, multiple tumour foci could be completely eradicated. Cancer Research reports on the results of this research in its online edition of 4th January.